T1	Participants 116 147	patients with advanced melanoma
T2	Participants 527 568	ipilimumab-induced gastrointestinal irAEs
T3	Participants 570 666	Treatment-naïve or previously treated patients with unresectable stage III/IV melanoma (n = 115)
